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Abstract 
Introduction: Our aim was to investigate the prescription patterns of antidepressant in the southern 
Israel during the years 2000 to 2005, before and after the FDA black box warning issued regarding the 
prescription of antidepressants in children.  
Patients and methods: A cross sectional study. Data regarding prescription of anti-depressant drugs 
was examined retrospectively. All information was obtained from the computerized databases of the 
Clalit Health care services, southern county. Data was analyzed by using descriptive statistics, and 
analytical statistics. Multi-variate analysis was performed when applicable. 
Results: When comparing the prescription rate of fluoxetine and fluvoxamine versus other SSRI’s 
included in the health agencies warnings during the years mentioned, there was a gradual increase in 
the percentage of the other SSRI’s until 2003 from 12.2% in 2000 to 64.2% in 2003 and then a reversal 
of this trend from 51.9% in 2004 to 47.8% in 2005. 
Discussion and conclusions: This study shows that the CSM advice has not had a significant effect in 
reversing the rising prevalence of antidepressant prescribed to children and adolescents in primary 
care. It has however changed the choice of antidepressant medication chosen within the group of 
SSRI’s.  
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1. Introduction 
Until recently, selective serotonin reuptake inhibitors (SSRIs) were among the most commonly 
prescribed medications in the world for the treatment of Major Depressive Disorder (MDD), in large part 
because they have been marketed as safe and effective. However, since the early 1990s, reports describe 
a possible association with suicidality (Leon et al., 1999). Recently, public health advisories expressing 
concern regarding the use of antidepressants for children were issued by the UK Committee on Safety of 
Medicines and the Food and Drug Administration (FDA) (Fergusson et al., 2005).  
Major depressive disorder (MDD) is a common disorder, with a lifetime prevalence of about 15 percent. 
The disorder is recognized in adults, adolescents and children and carries with it significant morbidity 
and even a risk of mortality. In adults the disorder is twice to three times more prevalent in women, 
reaching perhaps 25%. The mean age on onset is 40 years.  
Although the diagnostic category of depressive disorder in pediatric age used to be controversial, it is 
now well established that depressive disorders can and do occur in children and adolescents 
(Lewinsohn et al., 1993). The prevalence of depressive disorders is 1-2 percent of pre-pubertal children 
and 3-8 percent of adolescents, with a lifetime prevalence of approximately 20% by the end of 
adolescence. The female predominance seen in adults first emerges in adolescence (Zalsman, et al., 
2006). Treatment of depression among adolescents is important, because adolescence is a crucial 
period of life that strongly influences a person’s options for critical life choices.  
Depression is an important contributor to suicidal behavior and completed suicide in adolescents (Brent 
et al., 1999). Furthermore, depression in youths is a risk factor for depressive disorder, suicidal risk, 
and long-term psychosocial impairment in adulthood (Weissman et al., 1999). Suicide is the third 
leading cause of death in adolescents (Arias et al., 2003). Suicide is less common in childhood and 
early adolescence. Suicide incidence increases markedly in the late teens and continues to rise until the 
early twenties, reaching a level that is maintained throughout adulthood. The most likely reason 
underlying the age of onset of suicide is that depression and exposure to drugs and alcohol, two 
significant risk factors for suicide are rare in very young children and becomes prevalent only later 
adolescence (Gould et al., 2003). Although suicidal ideation and attempts are more common among 
females, completed suicide is more common among males. This pattern of sex differences does not 
exist in all countries. Completed suicide is more common in 15- to 24-year old males than females in 
North America, Western Europe, Australia, and New Zealand. Gender rates are equal in some countries 
in Asia (e.g., Singapore), and in China, the majority of suicides are committed by females (Gould et al., 
2003).  
Mood disorder, disruptive behavior disorder (DBD), and substance use disorder (SUD) are the three 
types of disorders that are most prevalent within the adolescent suicide victim population (Esposito & 
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Clum, 2002). Among these, depressive disorders are consistently the most prevalent disorders (Gould et 
al., 2003). The two most prominent risk factors for completed suicide and suicidal behavior in 
adolescents are past suicide attempts and a diagnosis of a depressive disorder, each of which 
independently contributes at least a 10-30 fold increased risk for completed suicide (Apter & King, 
2006).Clinically accepted treatments for major depressive disorder include various forms of 
psychotherapy and antidepressant medications. For first-line acute treatment of MDD in children and 
adolescents, the AACAP recommended psychotherapy, treatment with a selective serotonin reuptake 
inhibitor (SSRI), or both combined, depending on the patient, the patient’s circumstances, and the 
severity of disease. Studies in depressed youths have shown that cognitive-behavioral therapy (CBT) 
and interpersonal psychotherapy are efficacious for the acute treatment of depression (Birmaher et al., 
2000). Cognitive-behavioral therapy (CBT) as a treatment for MDD in youth has obtained strong 
empirical support for close to two decades .In the recent TADS study, it was found that compared with 
placebo, the combination of fluoxetine with CBT was statistically significant. Compared with 
fluoxetine, treatment of fluoxetine with CBT was superior. Fluoxetine alone was a superior treatment to 
CBT alone. The response rate for CBT alone was 43%, the response rate for medication was 61% and 
the response rate for combined treatment was 71%. (March et al., 2004) . But there have been few 
adequately powered controlled clinical trials in the area of MDD. Controlled studies of tricyclic 
antidepressant treatment for children and adolescents with depression failed to produce a replicable 
pattern of efficacy (March et al., 2004). Until recently SSRIs were recommended because of their 
relative safety, low lethality on overdose, and ease of administration (Emslie et al., 2002). The 
Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder 
recommended using fluoxetine, paroxetine, or sertraline first when medication is warranted for child 
and adolescent MDD (Emslie et al., 2002). The risk-benefit profile of individual SSRIs has been 
summarized in an article by Whittington et al. (2004) and more recently in a review by Moreno et al. 
(2006). Their analysis of published data from four trials of fluoxetine suggested a favorable risk-benefit 
profile for the treatment of depression in children and young adults; unpublished safety data lent 
support to this view. Published data from one trial of paroxetine and two unpublished suggested 
equivocal or weak positive risk-benefit profiles; two trials of Sertraline have been performed; when 
combining their results there was a small but significant improvement from baseline. Of two trials of 
Citalopram, of which the positive study was published, one study did not show efficacy, the other 
showed that the active drug was significantly better than placebo.  
But, two trials of venlafaxine and two trials of Mirtazapine suggested unfavorable risk-benefit profiles 
(Whittington et al., 2004; Moreno et al., 2006). In summary, there seems to be a controversy regarding 
the efficacy of Fluoxetine but not of other SSRI’s in the treatment of pediatric depression. Gibbons et al. 
(Gibbons et al., 2006) examined the association between antidepressant medication prescription rate 
and suicide rate in children ages 5-14. They found that higher SSRI prescription rates were associated 
with lower suicide rates in children and adolescents. Recently evidence was forwarded suggesting that 
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suicidality, primarily suicidal ideation, in children and adolescents may be increased by the newer 
antidepressant drugs, primarily selective serotonin-reuptake inhibitors. This raised concerns about the 
safety of SSRIs; in particular, the possibility that these drugs might be associated with an increased risk 
of suicidal behavior and that meaningful withdrawal reactions can happen while stopping treatment 
abruptly. Concerns in the USA about the safety of SSRIs prompted reviews by the US Food and Drug 
Administration and the American College of Neuropsychopharmacology. The FDA’s risk 
communication began in October 2003 when a public health advisory calling health care professionals’ 
attention to the possibility of an increased risk of suicidality in pediatric patients with depression, who 
were treated with antidepressant medications. The FDA announcements regarding unpublished efficacy 
studies suggested that negative results had not been made public. In June 2003, the FDA issued an alert 
citing uncontrolled studies showing a link between paroxetine treatment and suicide attempts among 
pediatric patients with depression. In March 2004, the FDA issued a strong warning calling on 
manufacturers of 10 specific antidepressants, mostly the newer agents, to add to their labeling a 
warning that all patients (adult and pediatric) being treated with these drugs should be monitored for 
suicidality. On September 14, 2004, a Food and Drug Administration (FDA) joint advisory committee 
recommended that a “black-box” warning label be required for antidepressant drugs, indicating that 
they increase the risk of suicidal thinking and behavior (“suicidality”) in pediatric patients. In February 
2005, the FDA provided specific language for the warning and required a patient medication guide 
(Newman, 2004; Libby et al., 2007). The Expert Working Group of the Committee on Safety of 
Medicines (CSM) undertook upon herself to review of the efficacy and safety of SSRIs in pediatric 
major depressive disorder. In view of the CSM review, the Medicines and Healthcare products 
Regulatory Agency (MHRA) released a statement contraindicating the use of all SSRIs other than 
fluoxetine as new treatment for patients younger than 18 years of age with depressive illness. This 
advice followed an earlier recommendation by the CSM that both paroxetine and venlafaxine should be 
contraindicated for use in this context (Emslie et al., 2002; Whittington et al., 2004).  
It is worth mentioning that although both these organizations raised concerns about the validity of the 
suicide data and called for further analyses, neither recommended contraindicating SSRIs (Whittington 
et al., 2004). Also the above does not address the safety and efficacy for treating other disorders seen in 
childhood, such as obsessive-compulsive disorder and anxiety with the same drugs (Whittington et al., 
2004). In December 2003 The Israel child and adolescent psychiatry association followed the FDA and 
issued a policy statement similar to that of the FDA, recommending first choice of Fluoxetine or 
Fluvoxamine for children for whom the treatment with an SSRI is indicated. In a study by Murray et al. 
(2005) comparing the prevalence and incidence of children and adolescents who were prescribed 
antidepressants in UK primary care, before and after the UK Committee on Safety of Medicines (CSM) 
advice on antidepressant prescribing, they found that antidepressant prevalence increased from 2000 to 
2002 and from 2002 to 2004 decreased. In this study the prevalence of CSM-contraindicated 
antidepressants declined by a third, but there was no change in fluoxetine prevalence. Kurdyak et al. 
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(2007) examined the prescribing trends in Canada in three age groups. They found that the number of 
new prescriptions for selective serotonin reuptake inhibitors as a group did not change, however, the 
rate of new Paroxetine prescriptions in patients younger than 20 years declined by 54% immediately 
after the first warning for Paroxetine was issued in the United Kingdom in June 2003. To our current 
knowledge no research has been done in Israel regarding the change in utilization of SSRI’s following 
the discussed developments. 
 
2. Methods 
2.1 General Aims of the Current Study 
The Main aim was to investigate the prescription patterns of antidepressant in the southern region of 
Israel during the years 2000 to 2005, before and after the FDA blackbox warning issued regarding the 
prescription of antidepressants in children under 18 years of age. We also wanted to describe 
prescription pattern of antidepressant drugs according to drug groups during 2000 and 2005. We tried to 
describe changes in prescribing practice of antidepressant prior to and following the FDA warning. 
2.2 Study Hypothesis 
We hypothesized, that following the FDA blackbox warning, prescriptions for antidepressant drugs for 
children less than 18 years of age will be reduced significantly. We thought that the fluoxetine and 
fluvoxamine were the most prescribe antidepressants as recommended by The Israel child and 
adolescent psychiatry association. 
2.3 Study Type 
A cross sectional study was performed. Data regarding prescription of anti depressant drugs was 
examined retrospectively.  
Period: We examined two time periods: from 2000 to 2003, prior to the FDA intervention, and from 
2004 to 2005, after the FDA intervention. We measured the % of change in the number of 
antidepressant type’s prescriptions. 
Independent variables used were: demographics (age, sex), number and types of antidepressant drugs 
(SSRI’s, Tricyclics, “Other” anti-depressants). 
Dependent variable was: The number of prescriptions issued for pediatric patients.  
Setting: The Negev region of Israel, a heterogeneously populated area with ~500,000 inhabitants (of 
whom >190,000 are under 18 years of age) belonging to 2 major ethnicities, Jewish and Moslem 
Bedouin.  
Both groups have similar mental care services provided mainly by the “Clalit Health Care Services”, 
the biggest (55% of market share) health maintenance organization in Israel. Psychiatric healthcare 
services are provided free of charge and are readily accessible in the community. Medical services are 
provided by primary care physicians who can prescribe antidepressants following a recommendation 
given by a board-certified child and adolescent psychiatrist. Six board certified psychiatrics, provide all 
psychiatric care in the region, treating over 80 percent of children under the age of 18.  
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Study population: Children under the age of 18, members of Clalit Health Care Services, who had been 
prescribed antidepressant medication by a primary care physician during the study period. We included 
all children, for whom the minimum effective dose of medication as defined in our study criteria was 
purchased. We used a serial number assigned in lieu of an identity number for each patient in order to 
identify repeat prescriptions.  
Data Sources: All information was obtained from the computerized databases of the Clalit Healt care 
services. The CHS billing system records contains more than 98% of all medical expenditures of the 
CHCS including all information on issued drugs (type, defined daily dose, number of tablets, and cost 
for each drug). All prescribed drugs, including antidepressants, are categorized according to the World 
Health Organization recommendations. 
Study protocol:  
  First, from the computerized database, of the Clalit Healt care services an inventory of all 
children under the age of 18 to whom antidepressant drugs were issued. 
  Antidepressant drugs were divided into three groups, that were analyzed according to the study 
variables. 
2.4 Study Definitions 
 The following groups of antidepressants were defined  
Selective serotonin reuptake inhibitors (SSRI’s): fluoxetine (flutine, affectine, prozac, prizma), 
fluvoxamine (favoxil), citalopram (cipramil), paroxetine (paxxet, seroxat), sertraline (lustral) 
Noradrenaline reuptake inhibitors: reboxetine (edronax)  
Serotonin and noradrenaline reuptake inhibitors: venlafaxine (efexor) 
Tricyclic drugs: Amitriptyline (Elatrolet, Elatrol), Clomipramine (Maronil, Anafranil), Imipramine 
(Primonil, Tofranil), Desipramine (Deprexan), Dibenzepin (Noveril, Victoril), Opipramol (Oprimol).  
Other antidepressant medications that are not recommended in children.  
 Appropriate treatment was defined as the purchase of a dose of antidepressant medication 
according to FDA recommendation (Fluoxetine) and Israeli recommendation (Fluoxetine and 
Fluvoxamine). 
 Inappropriate drug treatment was defined as the purchase of antidepressant not according to FDA 
recommendation medication i.e. all other anti-depressants.  
The quality of prescribing did not include dosages or length of treatment because children and adult 
receive dosages that are the same and not calculated by weight. 
Statistical analysis: The data was gathered from the records of the prescriptions. They were coded (to 
prevent any problems with subjects’ confidentiality) and then typed to SPSS statistical software (SPSS 
17.0). We analyzed the data first by using descriptive statistics (mean & SD, graphs), and then used 
analytical statistics using parametric tests: paired t-test, and a-parametric statistics: Mann Whitney & χ2. 
When primary analysis showed a significant effect of the use of drugs, we analyzed the data using 
repeated measurements ANOVA, and it’s a-parametric counterpart (The Friedman test).  
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3. Results 
Between the years 2000-2005 a total of 8344 anti-depressant prescriptions were issued for children 
under the age of 18 (see Table 1). Of these 5845 (70%) were prescriptions for SSRI’s, 1644 (19.7%) 
prescriptions for tricyclics, and 855 (10.2%) for other antidepressants - Moclobemide (1%) (7), 
Mianserin (1.8%) (16), Milnacepran (2.4%) (20), Mirtazapine (1.1%) (9), Reboxetine (50.3%) (430), 
Trazadone (2.1%) (18), Venlafaxine (41.5%) (355) (see Table 2).  
 
Table 1. Number of Anti-Depressant Medication Prescriptions Issued during the Years 2000-2005 
among Children and Percentage of Change during This Time Period 
Total Nm. SSRI’s 2 Percentage of change Nm. of patients Nm. of prescriptions1  Year 
613  983 0011 0111 
707 1 010 0011 0110 
976 08 082 0910 0110 
1109 01 068 0130 0119 
1262 00 902 0613 0111 
1178 0 916 0681 0111 
5845  0813 8911 Total 
1 Nm. of prescriptions issued in the Southern District of Kupat Holim Clalit for all anti-depressant 
medications to children under the age of 18. 
2 Number of prescriptions issued in the Southern District of Kupat Holim Clalit for all SSRI 
medications; Fluoxtine (Flutine, Affectine, Prozac, Prizma), Fluvoxamine (Favoxil), Citalopram 
(Cipramil, Recital), Sertraline (Lustral), Paroxetine (Paroxetine-Teva, Paxxet, Seroxat), Escitalopram 
(Cipralex) 
 
Table 2. Demographic Data and Number and Type of SSRI Anti-Depressant Medication 
Prescriptions Issued during the Years 2000-2005 among Children 
0111 0111 0119 0110 0110 0111 Year 
0681 0613 0130 0910 0011 0011 
Nm. of anti-depressant 
prescriptions1 
0028 0060 0013 326 212 609 Total Nm. SSRI’s 
1.21 1.26 1.21 1.21 1.61 1.16 
Ratio of total number of 
anti-depressant prescriptions.  
11.9/11.2  10.0/11.8  16.9/19.2  10.1/18.6  18.2/10.9  13.1/11.6  Male/Female Ratio (%) SSRI’s2 
01.10 01.90 01.08 01.36 01.12 01.22 Mean age SSRIs2 
601 612 932 112 166 198 Nm. “allowed” SSRI’s3 
10.6/18.1  11.1/11.1  10.3/18.0  61.3/93.0  11.6/11.1  11.0/13.8  Male/Female Ratio (%) 
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“allowed” SSRI’s9 
01.69 01.12 01.02 01.62 01.18 01.2 Mean age “allowed” SSRI’s 3 
169 611 200 103 010 21 Nm. “non-allowed” SSRI’s4 
12.0/10.8  11.8/11.0  19.0/16.3  19.1/16.1  91.9/61.2  11.1/16.1  
Male/Female Ratio (%) 
“non-allowed” SSRI’s4 
01.11 01.16 01.99 01.00 01.19 01.01 Mean age “non-allowed” SSRI’s4 
1 Nm. of prescriptions issued in the Southern District of Kupat Holim Clalit for all anti-depressant 
medications to children under the age of 18. 
2 Number of prescriptions issued in the Southern District of Kupat Holim Clalit for all SSRI 
medications; Fluoxtine (Flutine, Affectine, Prozac, Prizma), Fluvoxamine (Favoxil), Citalopram 
(Cipramil, Recital), Sertraline (Lustral), Paroxetine (Paroxetine-Teva, Paxxet, Seroxat), Escitalopram 
(Cipralex) 
 
Of the prescriptions for tricyclic antidepressants 1252 (76.2%) prescriptions were repeated 
prescriptions. The mean age of the patients who received prescriptions for SSRI’s was 15.04 (±2.86). 
The mean age of the patients who received prescriptions for tricyclics was 12.39 (±3.807).  
When comparing the prescription rate of fluoxetine and fluvoxamine versus other SSRI’s included in 
the health agencies warnings during the years mentioned, there was a gradual increase in the percentage 
of the other SSRI’s until 2003 from 12.2% in 2000 to 64.2% in 2003 and then a reversal of this trend 
from 51.9% in 2004 to 47.8% in 2005 (statistically significant <.001) (see Figure 1).  
 
0
500
1000
1500
2000
2001 2002 2003 2004 2005 2006
Years
N
u
m
b
e
r
 o
f 
P
r
e
s
c
r
ip
ti
o
n
s
Nm. Prescrption Nm. SSRI's
 
Figure 1. Number of Anti-Depressant Medication Prescriptions Issued during the Years 
2000-2006 among Children 
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There was no difference between the years regarding the prescription rate during different months. 
Males received 44% of the prescriptions for SSRI’s included in the health agencies warning and 
females 56.0% (statistically significant <.001).  
When comparing the years 2003 and 2004 there was a significant difference: 397 prescriptions (35.8%) 
for favoxil and Fluoxetine and 712 prescriptions (64.2%) for other SSRI’s in 2003 versus 607 
prescriptions (48.1%) for favoxil and Fluoxetine and 655 prescriptions (51.9%) for other SSRI’s in 
2004 (p ≤ 0.001).  
When comparing the years 2003 and 2005 there was a significant difference 397 prescriptions (35.8%) 
for favoxil and Fluoxetine and 712 prescriptions (64.2%) for other SSRI’s in 2003 versus 615 
prescriptions (52.2%) for favoxil and Fluoxetine and 563 prescriptions (47.8%) for other SSRI’s in 
2005 (p ≤ 0.001) .  
When comparing the years 2004 and 2005 there was a significant difference: 607 prescriptions (48.1%) 
for Fluvoxamine (favoxil) and Fluoxetine and 655 prescriptions (51.9%) for other SSRI’s in 2004 
versus 615 prescriptions (52.2%) for favoxil and Fluoxetine and 563 prescriptions (47.8%) for other 
SSRI’s in 2005 (p ≤ 0.05).  
When comparing the prescription rate of Fluoxetine versus all other SSRI’s, as included in the British 
and American health agencies warnings during the years mentioned, there was a gradual increase in the 
percentage of the other SSRI’s until 2003 from 47.3% in 2000 to 86% in 2003 and then a reversal of 
this trend from 74.3% in 2004 to 70.8% in 2005. 
When comparing the years 2003 and 2004 there was a significant difference: 155 prescriptions (14%) for 
Fluoxetine and 311 prescriptions (86%) for other SSRI’s in 2003 versus 324 prescriptions (25.7%) for 
Fluoxetine and 938 prescriptions (74.3 %) for other SSRI’s in 2004 (p ≤ to 0.001). When comparing the 
years 2003 and 2005 there was a significant difference 155 prescriptions (14%) for Fluoxetine and 311 
prescriptions (86%) for other SSRI’s in 2003 versus 344 prescriptions (29.2%) for Fluoxetine and 834 
prescriptions (70.8%) for other SSRI’s in 2005 (p ≤ to 0.001). When comparing the years 2004 and 2005 
there was not a significant difference: 324 prescriptions (25.7%) for Fluoxetine and 938 prescriptions 
(74.3%) for other SSRI’s in 2004 344 prescriptions (29.2%) for Fluoxetine and 834 prescriptions (70.8%) 
for other SSRI’s in 2005 (p ≤ 0.10.). When looking at the age of patients subscribed, we can see a steady 
decrease in age, as is seen in Figure 2. 
 
www.scholink.org/ojs/index.php/rhs                   Research in Health Science                         Vol. 4, No. 1, 2019 
10 
Published by SCHOLINK INC. 
200520042003200220012000
year of subsription
15.5
15
14.5
14
13.5
13
12.5
12
M
e
a
n
 
o
f
 
a
g
e
 
i
n
 
y
e
a
r
s
 
Figure 2. Mean Age of Patients’ Subscribed with of Anti-Depressant Medication Issued during 
the Years 2000-2006 among Children 
 
Summary: During the study period there was a rise in the number of patients prescribed SSRIs. 
However, from 2003 there was a decrease in prescriptions for CSM-contraindicated antidepressants 
(Citalopram, Escitalopram, Paroxetine, Sertraline and Venlafaxine). There was an increase in 
Fluoxetine and Fluvoxamine prescription prevalence. The number of patients prescribed tricyclic 
antidepressants dropped marginally.  
 
Table 3. Number and Type of Tricyclic Anti-Depressant Medication Prescriptions Issued during 
the Years 2001-2005 among Children and Demographic Data 
Mean age- tricyclics* Male/Female Ratio (%)-tricyclics* Nm. of tricyclics*  Year 
00.18 18.6/10.1  379 0111 
00.31 60.0/98.8  028 0110 
00.19 11.8/11.0  010 0110 
00.19 12.9/10.2  016 0119 
00.61 13.8/11.0  003 0111 
00.3 16.2/19.9  060 0111 
  0611 Total 
* Number of prescriptions issued in the Southern District of Kupat Holim Clalit for all tricyclic 
medications; Clomipramine (Anafranil, Maronil), Desipramine (Deprexan), Amitriptyline (Elatrol, 
Elatrolet) 
Doxapine (Gilex), Imipramine (Primonil, Tofranil), Maprotiline (Melodil), Nortriptyline (Nortylin) 
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Table 4. Number and Type of “Other” Anti-Depressant Medication Prescriptions Issued during 
the Years 2001-2005 among Children and Demographic Data 
Mean age- “other” 
anti-depressants* 
Male/Female Ratio (%)-”other” 
anti-depressants* 
Nm. “other” 
anti-depressants* 
Year 
01.81 11.0/13.8  112 0111 
01.01 18.8/10.0  003 0110 
01.06 20.6/08.1  21 0110 
01.68 10.8/18.0  092 0119 
09.9 21/01  068 0111 
00.09 21.1/01.1  011 0111 
  811 Total 
* Moclobemide (Mobemide), Mianserin (Bonserin), Reboxetine (Edronax), Ixel, Mirtazapine (Remeron, 
Miro) Trazodone (Trazodil, Trittico, Depyrel) Venflaxine (Efexor, Venla, Viepax)  
1 Nm. of prescriptions issued in the Southern District of Kupat Holim Clalit for all anti-depressant 
medications to children under the age of 18. 
2 Number of prescriptions issued in the Southern District of Kupat Holim Clalit for all tricyclic 
medications; Clomipramine (Anafranil, Maronil), Desipramine (Deprexan), Amitriptyline (Elatrol, 
Elatrolet) 
Doxapine (Gilex), Imipramine (Primonil, Tofranil), Maprotiline (Melodil), Nortriptyline (Nortylin) 
 
Table 5. Demographic Data and Number and Type of “Other” Anti-Depressant Medication 
Prescriptions Issued during the Years 2000-2005 among Children 
Mean age- “other” 
anti-depressants0 
Male/Female Ratio 
(%)-”other” 
anti-depressants0 
Ratio of total number 
of anti-depressant 
prescriptions 
Nm. “other” 
anti-depressants0 
Nm. of 
prescriptions1  
Year 
01.81 11.0/13.8  1.0 112 0011 0111 
01.01 18.8/10.0  1.0 003 0011 0110 
01.06 20.6/08.1  1.11 21 0910 0110 
01.68 10.8/18.0  1.13 092 0130 0119 
09.9 21/01  1.0 068 0613 0111 
00.09 21.1/01.1  1.01 011 0681 0111 
*** ** 1.0*  811 8911 Total 
1 Nm. of prescriptions issued in the Southern District of Kupat Holim Clalit for all anti-depressant 
medications to children under the age of 18. 
2 Moclobemide (Mobemide), Mianserin (Bonserin), Reboxetine (Edronax), Ixel, Mirtazapine (Remeron, 
Miro) Trazodone (Trazodil, Trittico, Depyrel) Venflaxine (Efexor, Venla, Viepax)  
* χ2 = 65.5, df = 5, p<0.001; ** χ2 = 43.9, df = 5, p<0.001; F(5,849)= 21.12, p<0.001 *** 
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4. Discussion 
Depression is a serious condition, associated with considerable morbidity and mortality; selective 
serotonin reuptake inhibitors (SSRIs) were commonly used in its treatment in child and adolescent 
psychiatry with increased prevalence until 2003. Our study shows that this is also true in the Negev 
Region of Israel, with increased use of SSRI’s other than Fluoxetine. In the wake of the UK Committee 
on Safety of Medicines (CSM) advice and the FDA’s issued black box warning, several studies 
attempted to review and study the connection between SSRIs and suicidality in children and 
adolescents. The findings were confusing and are insufficient at this time. There is insufficient safety 
information from randomized controlled trials to confirm a definite association between SSRIs and 
suicidality. We examined the prescribing practice regarding anti depressants especially SSRI’s in light 
of the current controversy over SSRI prescribing. Our study indicated that there has not been a decrease 
in prescriptions for children and adolescents. However, there has been a change in the choice of an 
SSRI. We conclude that even though there is still controversy as to whether there is indeed an increased 
risk of suicidality following treatment with anti-depressants in children and adolescents, physicians 
continue to treat depressive episodes with anti-depressants. This may be due to the fact that many of the 
prescriptions are prescribed directly by family physicians and are not based on a recommendation by a 
child psychiatrist, in which case the family physicians may be less aware of the above-mentioned 
warning. Were this true, however, there would probably have been no change at all in the prescribing 
trends which was not the case.  
There may also not be a reduction in the number of prescriptions issued due to a lack of available services 
and a paucity of therapists trained in evidence-based psychotherapies. The effect of the warnings on 
prescription rates may have occurred by directly targeting physicians or through change in client 
preference due to exposure of patients to information through the media.  
Our study points to the impact of change in policy by Regulatory agencies and shows that changes in 
policy can influence common practice even when the recommendation or warning is controversial and 
the evidence upon which it is based is debatable.  
Limitations of the study: Due to the use of the Kupat Holim Clalit data-base on the basis of prescribing 
information without accessing the patients’ files, we do not have information regarding diagnosis.  
One must remember that this is a retrospective study, and thus our ability to talk about causality is 
hampered. 
We did not interview physicians themselves and thus our results are based on assumptions which are 
logical but lack the insight from the prescribing physicians.  
Future studies: Further studies are needed to address whether the change we found in prescribing of 
anti-depressants is influenced by the child’s diagnosis and whether different anti-depressants are 
prescribed for diagnosis other than depression. 
Also, future studies need to address the factors taken into consideration when prescribing 
anti-depressive medication.  
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In addition, more studies are needed in order to examine whether indeed there has been a change in 
youth suicidality following the change in anti-depressant prescribing. 
 
5. Conclusions  
In our study we found an increase in antidepressant use over the years. Examining the prescription trend 
from 2000 we found that until 2003 there was an increase in the use of all SSRI’s. Since 2003, fewer 
children and adolescents have been prescribed antidepressants included in the CMS warnings. However 
in contrast to the study performed by Murray et al (Murray et al., 2005) we did find an increase in the use 
of fluoxetine and fluvoxamine. These medications were considered first choice treatments according to 
the recommendation issued by The Israel child and adolescent psychiatry association. This study shows 
that the CSM advice has not had a significant effect in reversing the rising prevalence of antidepressant 
prescribed to children and adolescents in primary care. It has however changed the choice of 
antidepressant medication chosen within the group of SSRI’s. Considering that the mean age for 
tricyclic prescriptions was approximately 2 years younger than that for SSRI’s, we can hypothesize that 
tricylics were prescribed for enuresis and not for depression. There is a slight decrease in prescription 
of tricyclics which does not seem to be significant indicating that physicians have chosen not to 
prescribe tricyclic medication as an alternative to SSRI’s. 
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